MRNA Add to watchlist $55.35 +1.12 (+2.07%) Last updated: Apr 22, 2026 14:19
52-Week Range
$55.35
$22.28 $55.35 $59.55

Fundamentals Overview

Moderna, Inc. is near the high of its 52-week range with premium valuation, trending upward today.

Valuation premium

P/B 2.51 P/S 11.25

Risk (Beta)

1.34 — higher vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 55% confidence Risk: High Volatility — Beta 1.34. Consider smaller position size due to higher beta.

Supporting (Buy):

3M vs S&P 500: +23.6% · 3M vs Healthcare sector: +33.6%

Pressures (Sell):

Sentiment weakening (1 downgrade) · Beta 1.34 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$21.86B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$22.28 - $59.55
Volume vs Avg
N/A
Beta
1.34

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus...
Sector: Healthcare
Headquarters: US
Employees: 5,800
IPO Date: Dec 2018
Beta: 1.34 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: C-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 3, Equal Weight: 8, Hold: 1, In Line: 2, Neutral: 2, Overweight: 2, Sector Perform: 4, Underperform: 5, Underweight: 3.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-1.54; current price is $55.35. That’s a -102.8% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 2.51
P/S (TTM) 11.25
Liquidity & enterprise
Current Ratio (TTM) 3.29
Quick Ratio (TTM) 3.22
Cash Ratio (TTM) 1.31
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -1.45%
Gross margin (TTM) 14.1%
Operating margin (TTM) -1.58%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for MRNA.

Analyst Sentiment at a Glance

C- Sentiment Weakening
Buy 3Equal Weight 8Hold 1In Line 2Neutral 2Overweight 2Sector Perform 4Underperform 5Underweight 3
0 upgrades, 1 downgrade
Price Target Consensus
Current $55.35
Median $35.00
Consensus $35.67
Low consensus $17.00
High consensus $63.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Barclays maintain Equal Weight Equal Weight 2026-04-02
Piper Sandler maintain Overweight Overweight 2026-02-23
Goldman Sachs maintain Neutral Neutral 2026-02-17
Evercore ISI Group maintain In Line In Line 2026-02-17
RBC Capital maintain Sector Perform Sector Perform 2026-02-17
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
RBC Capital maintain Sector Perform Sector Perform 2025-11-21
Leerink Partners maintain Underperform Underperform 2025-11-21
Piper Sandler maintain Overweight Overweight 2025-11-21
B of A Securities maintain Underperform Underperform 2025-11-10
Barclays maintain Equal Weight Equal Weight 2025-11-07
Citigroup maintain Neutral Neutral 2025-10-23
UBS maintain Buy Buy 2025-10-23
JP Morgan maintain Underweight Underweight 2025-10-23
Needham maintain Hold Hold 2025-10-20
Morgan Stanley maintain Equal Weight Equal Weight 2025-10-10
Leerink Partners maintain Underperform Underperform 2025-08-22
Barclays maintain Equal Weight Equal Weight 2025-08-04
B of A Securities maintain Underperform Underperform 2025-07-22
JP Morgan maintain Underweight Underweight 2025-05-22
RBC Capital maintain Sector Perform Sector Perform 2025-05-02
Evercore ISI Group maintain In Line In Line 2025-05-02
Barclays maintain Equal Weight Equal Weight 2025-05-02
UBS maintain Buy Buy 2025-05-02
Morgan Stanley maintain Equal Weight Equal Weight 2025-04-09
JP Morgan maintain Underweight Underweight 2025-03-21
UBS maintain Buy Buy 2025-02-19
Barclays downgrade Overweight Equal Weight 2025-02-18
RBC Capital maintain Sector Perform Sector Perform 2025-02-18
B of A Securities maintain Underperform Underperform 2025-02-11